Promising Results in Clinical Study for Acne Drug Candidate
SkinInc.com
Novan Therapeutics,announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers. This study in combination with Novan’s earlier findings regarding sebum production, suggests the formulation may be capable of targeting multiple factors in acne.
read all at
AsianScientist (Jun. 3, 2013) – By Sunanda Creagh – Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease, a condition commonly affecting small children that can lead to deadly infection of the brain and spinal cord membranes.
read all at
http://www.asianscientist.com/health-medicine/world-hand-foot-mouth-vaccine-developed-2013/
Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B cells by inhibiting their response to interleukin-2 (IL-2). Sirolimus is also used as a coronary stent coating.
A macrolide, sirolimus was discovered by Brazilian researchers as a product of the bacterium Streptomyces hygroscopicus in a soil sample from Easter Island — an island also known as Rapa Nui. It was approved by the FDA in September 1999 and is marketed under the trade name Rapamune by Pfizer (formerly by Wyeth).
Sirolimus was originally developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.
Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health …
BioNews Texas
Rapamycin Holdings will be looking to raise an additional $6 million as it approaches the point of taking its first drug product to Phase 1 clinical trials. On December 7, 2012, Rapamycin Holdings Chief Executive Officer George Fillis announced that …
read all at
http://newdrugapprovals.wordpress.com/2013/05/28/drug-manufacturing-presentation-processes/
DRUG MANUFACTURING PRESENTATION-PROCESSES
